Cargando…

Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN)

Mutations of JAK2V617F, CALR, and MPL genes confirm the diagnosis of myeloproliferative neoplasm (MPN). This study aims to determine the genetic profile of JAK2V617F, CALR exon 9 Type 1 (52 bp deletion) and Type 2 (5 bp insertion), and MPL W515 L/K genes among Malaysian patients and correlate these...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zulkeflee, Razan Hayati, Zulkafli, Zefarina, Johan, Muhammad Farid, Husin, Azlan, Islam, Md Asiful, Hassan, Rosline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307561/ https://www.ncbi.nlm.nih.gov/pubmed/34300032 http://dx.doi.org/10.3390/ijerph18147582

Ejemplares similares

Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms
por: Singdong, Roongrudee, et al.
Publicado: (2016)

Study of CALR, MPL, and c-kit Gene Mutations in Thai Patients with JAK2 V617F Negative Myeloproliferative Neoplasms
por: Wiriyaukaradecha, Kriangpol, et al.
Publicado: (2022)

Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL
por: Wang, Yan, et al.
Publicado: (2023)

Low JAK2 V617F Allele Burden in Ph-Negative Chronic Myeloproliferative Neoplasms Is Associated with Additional CALR or MPL Gene Mutations
por: Makarik, Tatiana V., et al.
Publicado: (2021)

Clonal independence of JAK2 and CALR or MPL mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing
por: Thompson, Ella R., et al.
Publicado: (2020)

JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Significance of combined detection of JAK2V617F, MPL and CALR gene mutations in patients with essential thrombocythemia
por: Ji, Liying, et al.
Publicado: (2017)

Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia
por: Vu, Hoang Anh, et al.
Publicado: (2019)

Correlation analysis between JAK2, MPL, and CALR mutations in patients with myeloproliferative neoplasms of Chinese Uygur and Han nationality and their clinical characteristics
por: Lang, Tao, et al.
Publicado: (2018)

JAK2, CALR, and MPL Mutation Profiles in BCR-ABL Negative Myeloproliferative Neoplasms, a Referral Center Experience in the Middle East
por: Safavi, Moeinadin, et al.
Publicado: (2021)

CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms
por: Belcic Mikic, Tanja, et al.
Publicado: (2019)

The Prevalence of TET2 Gene Mutations in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms (MPN): A Systematic Review and Meta-Analysis
por: Chia, Yuh Cai, et al.
Publicado: (2021)

Selected Parameters of Angiogenesis and the JAK2, CALR, and MPL Mutations in Patients With Essential Thrombocythemia
por: Gadomska, Grażyna, et al.
Publicado: (2018)

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling
por: Olschok, Kathrin, et al.
Publicado: (2023)

P1045: IS JAK2V617F BUT NOT CALR AS DRIVER MUTATION ENOUGH BY ITSELF IN THE PATHOGENESIS OF UNUSUAL TYPE VENOUS THROMBOSIS IN MPN PATIENTS?
por: Morsia, E., et al.
Publicado: (2022)

Prevalence of MPL (W515K/L) Mutations in Patients with Negative-JAK2 (V617F) Myeloproliferative Neoplasm in North-East of Iran
por: Shams, Seyyede Fatemeh, et al.
Publicado: (2018)

NK Cells in Myeloproliferative Neoplasms (MPN)
por: Naismith, Erin, et al.
Publicado: (2021)

P1008: THE TELOMERASE INHIBITOR IMETELSTAT DIFFERENTIALLY TARGETS JAK2V617F- VERSUS CALR-MUTANT MYELOPROLIFERATIVE NEOPLASM CELLS AND INHIBITS JAK-STAT SIGNALING
por: Olschok, Kathrin, et al.
Publicado: (2023)

CALR mutation characterization in myeloproliferative neoplasms
por: Bilbao-Sieyro, Cristina, et al.
Publicado: (2016)

PB2176: MRNA OF MPL AND JAK2 GENES IN PLATELETS IS ASSOCIATED WITH THEIR ASPIRIN RESISTANCE IN MPN PATIENTS
por: Stolyar, Marina, et al.
Publicado: (2023)

A Rare Co-Occurrence of Triple Mutations in JAK2, CALR, and MPL in the Same Patient with Myelofibrosis
por: Thomas, Sherine J., et al.
Publicado: (2022)

Renal biopsy cases in myeloproliferative neoplasms (MPN)
por: Fujita, Kumi, et al.
Publicado: (2013)

The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms
por: Belčič Mikič, Tanja, et al.
Publicado: (2021)

CALR mutations in myeloproliferative neoplasms: An unfolding story
por: Langabeer, Stephen E.
Publicado: (2020)

The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN
por: Spivak, Jerry L., et al.
Publicado: (2021)

Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish
por: Lim, K-H, et al.
Publicado: (2016)

The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms
por: Wu, Zhiyuan, et al.
Publicado: (2014)

A Multiplex Snapback Primer System for the Enrichment and Detection of JAK2 V617F and MPL W515L/K Mutations in Philadelphia-Negative Myeloproliferative Neoplasms
por: Wu, Zhiyuan, et al.
Publicado: (2014)

Low-level somatic JAK2 V617F mutation in myelodysplastic/ myeloproliferative neoplasm with ring sideroblasts, and thrombocytosis with co-mutated SF3B1 and CALR
por: Ji, Young Sok, et al.
Publicado: (2022)

Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives
por: Baumeister, Julian, et al.
Publicado: (2021)

Primary myelofibrosis with concurrent CALR and MPL mutations: A case report
por: Zhou, Feng-Ping, et al.
Publicado: (2020)

Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification
por: Hebeda, Konnie M., et al.
Publicado: (2009)

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
por: Kaifie, A., et al.
Publicado: (2016)

Two activating mutations of MPL in triple‐negative myeloproliferative neoplasms
por: Xie, Juan, et al.
Publicado: (2019)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Thromboinflammation in Myeloproliferative Neoplasms (MPN)—A Puzzle Still to Be Solved
por: Bhuria, Vikas, et al.
Publicado: (2022)

Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms
por: Cavalloni, Chiara, et al.
Publicado: (2017)

Development of paroxysmal nocturnal hemoglobinuria in CALR-positive myeloproliferative neoplasm
por: Fraiman, Yarden S, et al.
Publicado: (2016)

Concurrent chronic myeloid leukemia and CALR-mutated myeloproliferative neoplasm
por: Langabeer, Stephen E.
Publicado: (2020)

Effects of CALR-Mutant Type and Burden on the Phenotype of Myeloproliferative Neoplasms
por: Kim, Hyun-Young, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8051la62j021lpp35c70vdhr1q